Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aurelius Health Group vs OlleveCare

Aurelius Health Group
Graded #275

Higher grade

vs+16.099999999999994
OlleveCare
Graded #497

Lower grade

The verdict

Aurelius Health Group takes it — 62.3/100 to 46.2/100.

Aurelius Health Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aurelius Health Group is a telehealth platform built around compounded tirzepatide microdosing — a low-dose dual GIP/GLP-1 protocol rather than standard full-dose therapy — with optional NAD+, L-carnitine,…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAurelius Health Group +15
60
45
Dose & formulationAurelius Health Group +12
52
40
Clinical oversightAurelius Health Group +23
76
53
Labs & monitoringAurelius Health Group +14
63
49
FulfillmentAurelius Health Group +23
61
38
Contract termsAurelius Health Group +6
61
55
Aurelius Health Group · left barOlleveCare · right bar

The numbers

MetricAurelius Health GroupOlleveCare
WeighScore62.3/10046.2/100
GradeCC
Scorecard rank#275#497
SemaglutideNot disclosedNot disclosed
Tirzepatide$199/mo (microdose tier, compounded)Not disclosed
CoverageCoverage not published13 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Aurelius Health Group

Graded #275 · C

Strengths

  • Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
  • LegitScript Certified
  • Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
  • Unusually candid about the limited evidence base for microdosing

Where it loses points

  • Microdose-only model — sub-therapeutic doses have thinner trial evidence and likely smaller weight loss than full-dose tirzepatide
  • No semaglutide or standard full-dose option
  • No named compounding pharmacy partner
  • No state list and no named medical director or pharmacist-in-charge
OlleveCare

Graded #497 · C

Strengths

  • 13 states listed explicitly (VA, FL, AZ, MA, HI, IA, MD, NM, WA, KS, NY, DC, ID)
  • Both semaglutide and tirzepatide offered — switch molecules without switching platforms
  • Multi-service platform — GLP-1, virtual urgent care, and non-controlled refills with one provider
  • Cash-pay with a superbill option for out-of-network reimbursement
  • Founder Ahmed Emam is named in the footer

Where it loses points

  • Legal entity name not disclosed anywhere — can't be verified in a state registry
  • Pricing not shown before booking — you must enter the intake flow to see the fee
  • Pharmacy partner not named; model appears to fill at your preferred retail pharmacy
  • No medical director or prescribing clinician named — only 'board-certified providers'
  • No LegitScript badge, BBB profile, or HIPAA/SOC 2 seals displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard